Microbiome Connect : Gut Therapeutics Europe 2021

Microbiome Connect: Where innovation meets industry

Highlighting the Latest Clinical Research and Innovation in the Gut Microbiome Therapeutics Field

Register now
Amsterdam
7-8 December, 2021

“This event is a unique gathering of individuals from academia and industry who are collaborating to advance microbiome science. Kisaco has gone out of their way to include speakers and perspectives not found elsewhere. I look forward to attending again.”

KC Microbiome Communications Group

Why Attend

Microbiome Connect: Gut Therapeutics Europe is back to in-person format for the first time since 2019! This year, you will see numerous sessions dedicated to answering the arising challenges in both R&D and manufacturing.

The R&D stream will look at the gut-brain axis and provide solutions to clinical progression, commercialisation, and research result utilisation. Hear from Nestle, the University of Luxembourg, and more, to overcome challenges you are facing before you take your product to the market.

The manufacturing stream will help you to identify the right CDMO partner for a cost-effective and result-attaining collaboration, look at manufacturing and standardisation differences and update your knowledge on regulations in Europe and USA for your product protection.

Join us for two full days of innovation, discussion, and networking opportunities to further develop your knowledge and business opportunities in the gut microbiome therapeutics field.

200+
Attendees
50+
Leading Top Speakers
10+
Hours of Dedicated Networking

Who Will Be There

50%
Biotech and Pharmaceuticals
40%
Academics
10%
CDMO, CRO and Bioinformatics Companies

Biotech and Pharmaceuticals

Academics

CDMO, CRO and Bioinformatics Companies

Agenda

Find out the full speaker line-up for the first face to face event since 2019!

Following the success of previus events, please enter your details to download the full agenda for the upcoming Microbiome Connect: Gut Therapeutics Europe. You will discover our leading industry speakers, as well as our new 2021 dedicated manufacturing stream.

By attending the conference, you will:

  • Discover Industry Trends and Upcoming Targeted Indications for the Gut Microbiome Market from Stellate Therapeutics, Chr.Hansen and Utrecht university + Nutricia/Danone-Research.
  • Delve into manufacturing and standardisation regulations regarding LBP vs Probiotics with 4D Pharma
  • Explore novel microbiome molecule for hallmark of Parkinson's disease with Luxembourg Centre for Systems Biomedicine
  • Develop an IP strategy for microbiome therapeutics protection with Michèle Paquier, Head of Intellectual Property, Eligo Bioscience
  • Experience Four dedicated tracks for in-depth knowledge on Gut-Brain Axis, Manufacturing & Standardisation, Immun-oncology and Gastrointestinal.
  • Unveil the latest research insights with University College Cork on How the microbiome influences drug metabolism and how microbial modifications affect drug metabolism
  • Meet Europe’s leading biotech community: 4D Pharma, Everimmune, Stellate Therapeutics, Targedys and Microbiotica as we address the latest clinical research and manufacturing questions to ensure an optimised product strategy

Will you be joining...

Download our Agenda

Our Leading Microbiome Speakers

 

Grégory Lambert

VP & CEO Research and Development
Targedys

Pharmacist and Ph.D. in pharmaceutical technology, Gregory’s carrier is split between Biotech and Pharma where he occupied the positions of Chief Scientific Officer and Chief Executive Officer. Gregory drove the development of a number of drugs, medical devices and food supplement from the laboratory to market. Since 2014, Gregory is the CEO of TargEDys.

Grégory Lambert

VP & CEO Research and Development
Targedys

Grégory Lambert

VP & CEO Research and Development
Targedys

Pharmacist and Ph.D. in pharmaceutical technology, Gregory’s carrier is split between Biotech and Pharma where he occupied the positions of Chief Scientific Officer and Chief Executive Officer. Gregory drove the development of a number of drugs, medical devices and food supplement from the laboratory to market. Since 2014, Gregory is the CEO of TargEDys.

 

Adam Wilkinson

VP Pre-Clinical Development
Microbiotica

Adam Wilkinson

VP Pre-Clinical Development
Microbiotica

Adam Wilkinson

VP Pre-Clinical Development
Microbiotica
 

Benno Haarman

Psychiatrist
University Medical Center Groningen

Alongside continuing efforts to elucidate the pathophysiology of bipolar disorder, Dr. Haarman’s research currently focuses on the treatment of this severe psychiatric illness using immune modulating, psychosurgical and chronobiological therapies. In the field of psycho-immunology he is performing treatment studies in bipolar disorder using probiotics, diets and spinning.

Benno Haarman

Psychiatrist
University Medical Center Groningen

Benno Haarman

Psychiatrist
University Medical Center Groningen

Alongside continuing efforts to elucidate the pathophysiology of bipolar disorder, Dr. Haarman’s research currently focuses on the treatment of this severe psychiatric illness using immune modulating, psychosurgical and chronobiological therapies. In the field of psycho-immunology he is performing treatment studies in bipolar disorder using probiotics, diets and spinning.

 

Romaine Daillere

Co-Founder & Head of Preclinical Research
Everimmune

Romain Daillère completed his PhD in 2015 in the laboratory of Professor Laurence Zitvogel at the Gustave Roussy Cancer Campus (GRCC), Villejuif-Grand Paris/France. His research focuses on the complex interplay between gut microbiota and the efficacy of anticancer regimens. He previously graduated as a biotechnology engineer at the Ecole Supérieure de Biotechnology de Strasbourg (Trinational School of Strasbourg), and worked at the Ragon Institute of MIT, MGH and Harvard in Boston. Co-founder of EverImmune. Co-Inventor of EverImmune Technology.

Romaine Daillere

Co-Founder & Head of Preclinical Research
Everimmune

Romaine Daillere

Co-Founder & Head of Preclinical Research
Everimmune

Romain Daillère completed his PhD in 2015 in the laboratory of Professor Laurence Zitvogel at the Gustave Roussy Cancer Campus (GRCC), Villejuif-Grand Paris/France. His research focuses on the complex interplay between gut microbiota and the efficacy of anticancer regimens. He previously graduated as a biotechnology engineer at the Ecole Supérieure de Biotechnology de Strasbourg (Trinational School of Strasbourg), and worked at the Ragon Institute of MIT, MGH and Harvard in Boston. Co-founder of EverImmune. Co-Inventor of EverImmune Technology. He currently acts as head of the preclinical research of EverImmune.

 

Shahram Lavasani

Founder & CEO
ImmuneBiotech

Dr. Shahram Lavasani is an international keynote speaker and entrepreneur in the field of the microbiome. He received his PhD in Immunology from Lund University/Sweden. With more than two decades of teaching and research expertise on Gut-Brain axis, he has pioneered research in multiple sclerosis by demonstrating gut inflammation and barrier dysfunction and introduced microbiota-based therapies using probiotic bacterial consortia. He is the founder of ImmuneBiotech developing novel microbiome therapeutics.

Shahram Lavasani

Founder & CEO
ImmuneBiotech

Shahram Lavasani

Founder & CEO
ImmuneBiotech

Dr. Shahram Lavasani is an international keynote speaker and entrepreneur in the field of the microbiome. He received his PhD in Immunology from Lund University/Sweden. With more than two decades of teaching and research expertise on Gut-Brain axis, he has pioneered research in multiple sclerosis by demonstrating gut inflammation and barrier dysfunction and introduced microbiota-based therapies using probiotic bacterial consortia. He is the founder of ImmuneBiotech developing novel microbiome therapeutics. The company has access to a proprietary lactobacilli library and advanced selection technologies to design nutritional formulations for optimal management of the diseases. ImmuneBiotech´s first product GutMagnific® has been designed to address the underlying causes of IBS and it is currently investigated, in collaboration with Karolinska Institute, for treatment of chronic fatigue syndrome (ME/CFS) a neuroimmune condition and a possible long-term effect of Covid-19. GutMagnific® has successfully been launched in October 2019. 

 

Marcus Böhme

Gut-Brain Axis R&D Specialist
Nestlé

Dr. Marcus Böhme is a R&D Specialist working at the Nestlé Research Centre in Lausanne, Switzerland where he is leading projects on the Gut-Brain Axis. Prior to joining Nestlé, he completed his undergraduate training in Nutritional Science at the Friedrich-Schiller-University Jena, Germany, where he also received his PhD in Neuroscience. Subsequently, Dr. Böhme undertook a 4-year postdoctoral fellowship in the lab of Prof. John Cryan at the University College Cork, Ireland, where he studied the role of the gut microbiome on brain and cognitive health across the lifespan.

Marcus Böhme

Gut-Brain Axis R&D Specialist
Nestlé

Marcus Böhme

Gut-Brain Axis R&D Specialist
Nestlé

Dr. Marcus Böhme is a R&D Specialist working at the Nestlé Research Centre in Lausanne, Switzerland where he is leading projects on the Gut-Brain Axis. Prior to joining Nestlé, he completed his undergraduate training in Nutritional Science at the Friedrich-Schiller-University Jena, Germany, where he also received his PhD in Neuroscience. Subsequently, Dr. Böhme undertook a 4-year postdoctoral fellowship in the lab of Prof. John Cryan at the University College Cork, Ireland, where he studied the role of the gut microbiome on brain and cognitive health across the lifespan. His research focusses on how diet shapes brain health and behavior with the gut microbiota acting as a novel mediator between diet and maintenance of brain health.

 

Paul Wilmes

Professor of Systems Ecology, Luxembourg Centre for Systems Biomedicine
University of Luxembourg

Paul Wilmes

Professor of Systems Ecology, Luxembourg Centre for Systems Biomedicine
University of Luxembourg

Paul Wilmes

Professor of Systems Ecology, Luxembourg Centre for Systems Biomedicine
University of Luxembourg
 

Boushra Dalile

senior PhD researcher_ Translational Research Center in Gastrointestinal Disorders (TARGID)
KU Leuven

Boushra Dalile is a senior PhD researcher. She graduated with a BA in Psychology from Swinburne University of Technology, Australia, an MS.c. in Cognitive Neuroscience from the University of Skövde, Sweden, and will soon graduate with a PhD in Biomedical Sciences from the KU Leuven in Belgium. She conducts interdisciplinary research investigating the influence of nutrition-related interventions on sensitivity to psychosocial stress and anxiety-related processes, with the aim of unveiling mechanisms of action..

Boushra Dalile

senior PhD researcher_ Translational Research Center in Gastrointestinal Disorders (TARGID)
KU Leuven

Boushra Dalile

senior PhD researcher_ Translational Research Center in Gastrointestinal Disorders (TARGID)
KU Leuven

Boushra Dalile is a senior PhD researcher. She graduated with a BA in Psychology from Swinburne University of Technology, Australia, an MS.c. in Cognitive Neuroscience from the University of Skövde, Sweden, and will soon graduate with a PhD in Biomedical Sciences from the KU Leuven in Belgium. She conducts interdisciplinary research investigating the influence of nutrition-related interventions on sensitivity to psychosocial stress and anxiety-related processes, with the aim of unveiling mechanisms of action.. Specifically, she focuses on the effects of dietary fiber and the role of short-chain fatty acids in the human microbiota-gut-brain axis. Her scientific work contributed to multiple conference abstracts and peer-reviewed publications.

 

Jonathan Weiss

PhD, MBA
VP of Corporate and Business Development

Dr. Weiss completed his PhD at the NYU School of Medicine where he studied immune tolerance through the interactions of Treg and Th17 cells. Upon graduation he began working at Kadmon Pharmaceuticals as a scientist developing the first ROCK2 inhibitor. The drug, Rezurock (Belumosudil), was granted Orphan Drug and Breakthrough Therapy Designations by the FDA and bypassed a Phase III clinical trial. The drug was approved by the FDA in August 2021 for Chronic Graft Versus Host Disease (cGVHD). After completing his MBA, Dr.

Jonathan Weiss

PhD, MBA
VP of Corporate and Business Development

Jonathan Weiss

PhD, MBA
VP of Corporate and Business Development

Dr. Weiss completed his PhD at the NYU School of Medicine where he studied immune tolerance through the interactions of Treg and Th17 cells. Upon graduation he began working at Kadmon Pharmaceuticals as a scientist developing the first ROCK2 inhibitor. The drug, Rezurock (Belumosudil), was granted Orphan Drug and Breakthrough Therapy Designations by the FDA and bypassed a Phase III clinical trial. The drug was approved by the FDA in August 2021 for Chronic Graft Versus Host Disease (cGVHD). After completing his MBA, Dr. Weiss joined the Stellate Therapeutics team to help move their therapeutics programs towards the clinic.

 

Lukas Van Oudenhove

Professor, Translational Research Center for Gastrointestinal Disorders
University of Leuven

Lukas graduated as a Medical Doctor at KU Leuven in 2001. During his specialist training in psychiatry, he was granted a PhD-fellowship of the Research Foundation – Flanders, resulting in his doctoral thesis ‘Psychobiological mechanisms in functional dyspepsia. Converging evidence from psychophysiology & functional brain imaging?’ (KU Leuven, 2008). He then worked as a postdoctoral fellow of the Research Foundation – Flanders at the Translational Research Center for Gastrointestinal Diseases (TARGID) of KU Leuven from 2009 until 2012.

Lukas Van Oudenhove

Professor, Translational Research Center for Gastrointestinal Disorders
University of Leuven

Lukas Van Oudenhove

Professor, Translational Research Center for Gastrointestinal Disorders
University of Leuven

Lukas graduated as a Medical Doctor at KU Leuven in 2001. During his specialist training in psychiatry, he was granted a PhD-fellowship of the Research Foundation – Flanders, resulting in his doctoral thesis ‘Psychobiological mechanisms in functional dyspepsia. Converging evidence from psychophysiology & functional brain imaging?’ (KU Leuven, 2008). He then worked as a postdoctoral fellow of the Research Foundation – Flanders at the Translational Research Center for Gastrointestinal Diseases (TARGID) of KU Leuven from 2009 until 2012. In 2012, he was appointed assistant research professor of the KU Leuven Special Research Fund, allowing him to establish his own group, the Laboratory for Brain-Gut Axis Studies (LaBGAS). His research has been internationally authoritative, as reflected by more than 200 peer-reviewed publications, numerous invited and abstract presentations at scientific meetings, and several international research awards. In 2020, Lukas got granted an ERC Consolidator Grant MoodBugs, focus on microbiota-gut-brain signaling mechanisms mediating the impact of the gut microbiota on stress and fear responses in humans.

 

Adam Baker

Director of Sciences
Chr. Hansen

Director of Science responsible for the research of current and next-generation probiotics, and building a strong portfolio of scientific data to support our commercial probiotic business.
We focus on the key role of bacteria throughout life and how these bacteria play key roles in our health. In particular, we are focused on the interactions between the bacteria and the host microbiome at a molecular and clinically functional level.

Adam Baker

Director of Sciences
Chr. Hansen

Adam Baker

Director of Sciences
Chr. Hansen

Director of Science responsible for the research of current and next-generation probiotics, and building a strong portfolio of scientific data to support our commercial probiotic business.
We focus on the key role of bacteria throughout life and how these bacteria play key roles in our health. In particular, we are focused on the interactions between the bacteria and the host microbiome at a molecular and clinically functional level.

Prior to Chr. Hansen worked as the VP of Diagnostic Product Develop at Exiqon A/S in Denmark for 5 years and the Head of New Technologies in deCODE Genetics in Iceland.

 

Céline Durant

Microbiome Project Manager
PRI

Céline Durant

Microbiome Project Manager
PRI

Céline Durant

Microbiome Project Manager
PRI
 

Christopher Carite

CMC & Development SVP
4D Pharma

Christophe is a French citizen graduated in industrial pharmacy (PharmD), Microbiology and Business Administration. He has started his industrial career as plant manager for Lallemand Bacteria Division early ninety, then occupied various positions in R&D and Marketing in B2B of Pharmaceuticals Ingredients.

Christopher Carite

CMC & Development SVP
4D Pharma

Christopher Carite

CMC & Development SVP
4D Pharma

Christophe is a French citizen graduated in industrial pharmacy (PharmD), Microbiology and Business Administration. He has started his industrial career as plant manager for Lallemand Bacteria Division early ninety, then occupied various positions in R&D and Marketing in B2B of Pharmaceuticals Ingredients. He has joined 4D pharma at the early beginning of the company in 2014 and he has assumed the challenge to produce  freeze dried strict anaerobic bacteria at the industrial scale level ( 3500 L fermentor, 5 to 20m2 Freeze dryer) to deliver high concentrated LBPs  to patients (> 1010 CFU/caps, shelf life up to 2 years) recognised by several patent families granted. In addition, Christophe has integrated “in house” all 4D pharma Manufacturing and Controls under inspected cGMP.

Right now, he assume the position of Process development/CMC Director and member of 4D Pharma Executive team reporting directly to the CEO.

 

Denise Kelly

Consultant
Seventure

Denise Kelly

Consultant
Seventure

Denise Kelly

Consultant
Seventure
 

Johan Garrsen

Director/Professor
Utrecht university + Nutricia/Danone-Research

Johan Garrsen

Director/Professor
Utrecht university + Nutricia/Danone-Research

Johan Garrsen

Director/Professor
Utrecht university + Nutricia/Danone-Research
 

Jose A Villa Rodriguez

Sr Scientist NA, Global Nutrition Science
Reckitt (TBC)

Jose A Villa Rodriguez

Sr Scientist NA, Global Nutrition Science
Reckitt (TBC)

Jose A Villa Rodriguez

Sr Scientist NA, Global Nutrition Science
Reckitt (TBC)
 

Michèle Paquier

Head of Intellectual Property
Eligo Bioscience

Michèle has 15+ years of experience in the biotech field, mostly genome engineering, where she has developed IP strategy, managing know-how and large international patents portfolio to support research, commercial and legal activities as a true business partner.

Michèle is heading the IP activity of Eligo Bioscience, a biotech company developing a first-in-class proprietary technology to engineer the microbiome and change the genetic signature of the microbiome with unprecedented precision.

Michèle Paquier

Head of Intellectual Property
Eligo Bioscience

Michèle Paquier

Head of Intellectual Property
Eligo Bioscience

Michèle has 15+ years of experience in the biotech field, mostly genome engineering, where she has developed IP strategy, managing know-how and large international patents portfolio to support research, commercial and legal activities as a true business partner.

Michèle is heading the IP activity of Eligo Bioscience, a biotech company developing a first-in-class proprietary technology to engineer the microbiome and change the genetic signature of the microbiome with unprecedented precision.

In the past, Michèle worked over 6 years with Cellectis, a pioneering biotech company in genome engineering. She is also a former IP expert of Bpifrance (French Public Investment Bank).

 

 

Niall Hyland

Senior Lecturer, Department of Physiology
University College Cork

Niall Hyland

Senior Lecturer, Department of Physiology
University College Cork

Niall Hyland

Senior Lecturer, Department of Physiology
University College Cork
 

Robert Jan Brummer

Professor of Gastroenterology and Clinical Nutrition
Orebro University

Robert JM Brummer is professor of Gastroenterology and Clinical Nutrition and senior consultant at Örebro University and University Hospital, Sweden. He is director of the interdisciplinary Nutrition-Gut-Brain Research Centre as well as the national research excellence centre PAN Sweden (Plant-based Proteins for Health and Well-being). As Pro-Vice-Chancellor of the University he leads the University Food and Health Strategic Programme that comprises all Faculties and Schools of the University.

Robert Jan Brummer

Professor of Gastroenterology and Clinical Nutrition
Orebro University

Robert Jan Brummer

Professor of Gastroenterology and Clinical Nutrition
Orebro University

Robert JM Brummer is professor of Gastroenterology and Clinical Nutrition and senior consultant at Örebro University and University Hospital, Sweden. He is director of the interdisciplinary Nutrition-Gut-Brain Research Centre as well as the national research excellence centre PAN Sweden (Plant-based Proteins for Health and Well-being). As Pro-Vice-Chancellor of the University he leads the University Food and Health Strategic Programme that comprises all Faculties and Schools of the University. Brummer is engaged in (inter)national boards and strategies regarding food and nutrition research and innovation and acts as reviewer for several international research councils.

 

Sophie Durand

CEO
Stellate Therapeutics

Sophie Durand

CEO
Stellate Therapeutics

Sophie Durand

CEO
Stellate Therapeutics
 

Wouter J de Jonge

Professor of Exp. Gastroenterology
Amsterdam UMC

Prof. dr. Wouter de Jonge, AGAF, received his doctoral training at University of Utrecht, and Columbia University New York, and received his PhD in 2001 (Medicine, University of Amsterdam and Maastricht). He took up postdoctoral positions at the AMC in Amsterdam (prof Guy Boeckxstaens-now in Leuven) and Oxford University (prof Siamon Gordon). He was appointed tenured assistant professor at Amsterdam UMC in 2009 and was appointed full professor in 2013.

Wouter J de Jonge

Professor of Exp. Gastroenterology
Amsterdam UMC

Wouter J de Jonge

Professor of Exp. Gastroenterology
Amsterdam UMC

Prof. dr. Wouter de Jonge, AGAF, received his doctoral training at University of Utrecht, and Columbia University New York, and received his PhD in 2001 (Medicine, University of Amsterdam and Maastricht). He took up postdoctoral positions at the AMC in Amsterdam (prof Guy Boeckxstaens-now in Leuven) and Oxford University (prof Siamon Gordon). He was appointed tenured assistant professor at Amsterdam UMC in 2009 and was appointed full professor in 2013. He currently chairs the gastro-intestinal research group (www.gut-research.com) at the Amsterdam UMC since 2013 and holds a part time professorship at the Dept of Surgery at the University of Bonn, Germany since 2018.  

His work focusses on translational gastroenterology and the pathology of IBD. He is interested in gastrointestinal physiology and the function of neural networks within the gastrointestinal tract, in particular in relation to IBS and IBD.  His work is funded via national Science Foundation grants (NWO-Vidi-STW), EU FP7, ECCO, and 2 Horizon2020 grants, Helmsley Foundation, Health Holland TKI topsector grants, and various public private partnership grants. He was co-founder of the Microbiome Center Amsterdam in 2016. He holds 5 patents. He served on the board of the scientific committees a.o. Dutch national trust for Gastro Intestinal and Lever Diseases, EU Marie Curie grants, AMC Valorisation Board, and serves as CEO on a spin off company AI-Biomics B.V., a company that develops predictive algorithms for disease biomarkers.  

 

 

Yolanda Sanz Herranz

Senior Researcher
CSIC

Yolanda Sanz Herranz

Senior Researcher
CSIC

Yolanda Sanz Herranz

Senior Researcher
CSIC
 

Tuval Ben-Yehezkel, PhD

CEO
Loop Genomics

Tuval Ben-Yehezkel is a scientist-entrepreneur focused on applied genomics and synthetic biology. Authored key patents, publications and book chapters in synthetic biology and genomics. Founded and secured $15.3M in funding for two biotech start-up companies.

Tuval Ben-Yehezkel, PhD

CEO
Loop Genomics

Tuval Ben-Yehezkel, PhD

CEO
Loop Genomics

Tuval Ben-Yehezkel is a scientist-entrepreneur focused on applied genomics and synthetic biology. Authored key patents, publications and book chapters in synthetic biology and genomics. Founded and secured $15.3M in funding for two biotech start-up companies.

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:

Early Bird Ends Friday 29 October

Thursday, September 23, 2021 to Friday, October 29, 2021
Academics & Research Institutions
€999 + VAT
Early Bird rate until Friday 29 October (Standard €1299)
Access to Microbiome Connect: Skin
2 Day In-Person Conference Pass
In-Person networking opportunities
Saturday, October 2, 2021 to Friday, October 29, 2021
Biotech, Pharma and Industry
€1499 + VAT
Early Bird rate until Friday 29 October (Standard €1699)
Access to Microbiome Connect: Skin
2 Day In-Person Conference Pass
In-Person networking opportunities
Saturday, October 2, 2021 to Friday, October 29, 2021
Vendors
€2399 + VAT
Early Bird rate until Friday 29 October (Standard €3099)
Access to Microbiome Connect: Skin
2 Day In-Person Conference Pass
In-Person networking opportunities
Preparing registration...

TESTIMONIALS

OUR MICROBIOME COMMUNITY

Sponsors

Gold Event Partner

Silver Event Partner

Bronze Event Partner

Event Partner

Media Partners

Become a Partner

Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.

Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.

Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].

Resources

Download Resource

Venue

Hilton Amsterdam Apollolaan 138 Amsterdam 1077 BG The Netherlands

We are delighted to be hosting the event in Amsterdam this year!

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us

Other events you might be interested in:

Microbiome Connect : Gut Therapeutics